A US FDA investigation of CRO PPD did not uncover any violations that might prompt a Form 483 for its work related to Bristol-Myers Squibb’s approved drug, Eliquis.
Charles River Laboratories has partnered with eCRO Target Health and Theorem Clinical Research to support the transfer and validation of assays supporting the CROs’ preclinical programs.
As GlaxoSmithKline, Bristol-Myers Squibb and Novartis are embroiled in alleged bribery and data falsification in Asia, CROs will have to a take a hard look at whether their investments in the region will pay off as quickly as they once thought.
